{"id":"W4401942365","doi":"10.1182/blood.2024024582","title":"Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary","funders":"Pharmacyclics; Chugai Pharmaceutical; BeiGene; Regeneron Pharmaceuticals; American Society of Clinical Oncology; Bristol-Myers Squibb; AstraZeneca; National Cancer Research Institute; Gilead Sciences; Sanofi; Celgene; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Hazard ratio; Internal medicine; Clinical endpoint; Progression-free survival; Confidence interval; Interim analysis; Multiple myeloma; Lenalidomide; Refractory (planetary science); Gastroenterology; Tolerability; Surgery; Randomized controlled trial; Adverse effect; Overall survival","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003661239,0.0003230398,0.0006090975,0.0005987243,0.000098125,0.00009737279,0.0001101339,0.000197574,0.0002199675],"category_scores_gemma":[0.0005412059,0.0002564806,0.0001440984,0.0007119494,0.0001305889,0.0001935958,0.00008816187,0.000511412,0.000102705],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000173681,"about_ca_system_score_gemma":0.0003248295,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002098156,"about_ca_topic_score_gemma":0.0002539459,"domain_scores_codex":[0.9974685,0.0001596356,0.0004813987,0.0006843258,0.0006047097,0.000601444],"domain_scores_gemma":[0.9985826,0.0003295021,0.00006391661,0.0005023582,0.0001098151,0.0004118225],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.01158086,0.005313729,0.4461531,0.001184857,0.004660109,0.02505008,0.001868418,0.000005345149,0.4622324,0.0002441245,0.01986975,0.0218372],"study_design_scores_gemma":[0.1229392,0.006444091,0.5498974,0.001785039,0.00212621,0.0006739582,0.0008443624,0.004215505,0.2515668,0.0003084711,0.05794336,0.001255617],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9902637,0.005180941,0.00002208282,0.0008055049,0.0001396628,0.0008517615,0.0001551442,0.0002504015,0.002330777],"genre_scores_gemma":[0.9951707,0.0005172903,0.0009660068,0.00009526069,0.0001150113,0.00007319721,0.0003145291,0.00006507352,0.002682911],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2106657,"threshold_uncertainty_score":0.9999887,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04194345554366068,"score_gpt":0.3349759606370604,"score_spread":0.2930325050933997,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}